| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6592903 | ENDO PHARMS INC | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
| US9101540 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(3 days ago) | |
| US7101576 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(3 days ago) | |
| US9107827 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(3 days ago) | |
| US9101549 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(3 days ago) | |
| US9040088 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(3 days ago) | |
Megace Es is owned by Endo Pharms Inc.
Megace Es contains Megestrol Acetate.
Megace Es has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Megace Es are:
- US6592903
- US9101540
- US7101576
- US9107827
- US9101549
- US9040088
Megace Es was authorised for market use on 05 July, 2005.
Megace Es is available in suspension;oral dosage forms.
Megace Es can be used as treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids).
The generics of Megace Es are possible to be released after 22 April, 2024.
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION;ORAL
MEGACE ES family patents
